Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 4, 2010, Pages 231-238

  Cannizzo, Elisa ^a,b   Bellio, Emanuele ^b   Sohani, Aliyah R ^a   Hasserjian, Robert P ^a   Ferry, Judith A ^a   Dorn, Michelle E ^a   Sadowski, Craig ^a   Bucci, Janessa J ^a   Carulli, Giovanni ^b   Preffer, Frederic ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Flow cytometry; Multiparameter flow cytometry; Multiple myeloma; Polyclonal plasma cells' immunophenotype; Ranges of normal antigenic expression

Indexed keywords

CD19 ANTIGEN; CD200 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; STEM CELL FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REFERENCE VALUE; SCREENING TEST; CONFIDENCE INTERVAL; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CONFIDENCE INTERVALS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PLASMA CELLS; REFERENCE VALUES;

EID: 77956525540     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20517     Document Type: Article

References (50)

1. Munker R, Hiller E, Paquette R. Modern hematology: Biology and clinical management, 2nd ed. Totowa, NY: Humana Press Inc; 2007. 250 p.
2. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431-438. (Pubitemid 351398645)
3. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005;90:706-707. (Pubitemid 40780900)
4. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-4197. (Pubitemid 44913292)
5. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105:4845-4848. (Pubitemid 40807312)
6. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004;89:547-551. (Pubitemid 38691241)
7. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, Lopez-Berges C, Moro MJ, Hernandez J, Escribano L, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-1665. (Pubitemid 28275024)
8. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, et al. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol 1997;97:46-55. (Pubitemid 27179563)
9. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990;76:1739-1747.
10. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, Galende J, Martin-Nunez G, Alonso JM, de Las Heras N, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586-2592. (Pubitemid 47523182)
11. San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer 2006;42:1510-1519.
12. Sezer O, Heider U, Zavrski I, Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001;86:837-843. (Pubitemid 32847445)
13. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, Rosinol L, Montejano L, Blade J, Martinez R, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737-2744.
14. Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007;40:1033-1037. (Pubitemid 350142555)
15. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006;91:1234-1240.
16. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003;102:1070-1071. (Pubitemid 36917806)
17. Matsuda I, Mori Y, Nakagawa Y, Sawanobori M, Uemura N, Suzuki K. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11; 14) in multiple myeloma]. Rinsho Ketsueki 2005;46:1293-1297.
18. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An eastern cooperative oncology group study. Cancer Res 2002;62:715-720. (Pubitemid 34126946)
19. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML, Hernandez JM, Lopez-Berges MC, Montejano L, Blade J, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005;11:3661-3667. (Pubitemid 40685582)
20. Lima M, Teixeira Mdos A, Fonseca S, Goncalves C, Guerra M, Queiros ML, Santos AH, Coutinho A, Pinho L, Marques L, et al. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis 2000;26:634-645.
21. San Miguel JF, Gonzalez M, Gascon A, Moro MJ, Hernandez JM, Ortega F, Jimenez R, Guerras L, Romero M, Casanova F, et al. Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991;77:185-190.
22. Liu H, Yuan C, Heinerich J, Braylan R, Chang M, Wingard J, Moreb J. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. Leuk Lymphoma 2008;49:306-314. (Pubitemid 351193924)
23. Lemoli RM, Fortuna A C-kit ligand (SCF) in human multiple myeloma cells. Leuk Lymphoma 1996;20(5-6):457-464.
24. Potti A, Ganti AK, Koch M, Levitt R, Mehdi SA. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. Leuk Lymphoma 2002;43:2427-2430. (Pubitemid 35386171)
25. Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 2004;444:264-268. (Pubitemid 38446439)
26. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008;141:135-148. (Pubitemid 351406208)
27. Riley JK, Sliwkowski MX CD20: A gene in search of a function. Semin Oncol 2000;27(Suppl 12):17-24.
28. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: The new and the old. Blood Rev 2004;18:17-37. (Pubitemid 38200499)
29. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, Fernandez-Calvo J, Sanz MA, Perez-Simon JA, Rasillo A, et al. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032-1037. (Pubitemid 29067869)
30. Buda G, Carulli G, Orciuolo E, Cannizzo E, Zucca A, Azzara A, Rossi A, Galimberti S, Cecconi N, Petrini M. Two cases of plasma cell leukemia with atypical immunophenotype. Acta Haematol 2007;118:27-29. (Pubitemid 47014337)
31. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992;6:297-322.
32. Bergsagel DE. The role of chemotherapy in the treatment of multiple myeloma. Baillieres Clin Haematol 1995;8:783-794. (Pubitemid 26014362)
33. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, et al. CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications. J Immunother 2002;25:72-81. (Pubitemid 34052837)
34. Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Herault O, Garnache F, Garand R, Varoqueaux N, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007;21:835-836. (Pubitemid 46444580)
35. Alcindor T, Kimlinger T, Witzig TE. High expression of CD59 and CD55 on benign and malignant plasma cells. Leuk Lymphoma 2006;47:919-921. (Pubitemid 43840650)
36. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
37. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma 2006;47:39-42. (Pubitemid 43101722)
38. Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 2007;127:176-181. (Pubitemid 46797173)
39. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488. (Pubitemid 38392955)
40. Kraj M, Poglod R, Kopec-Szlezak J, Sokolowska U, Wozniak J, Kruk B. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004;45:2281-2289. (Pubitemid 39504323)
41. Cserti-Gazdewich CM, Dzik WH, Dorn ME, Quagliaroli RO, Xu S, Ssewanyana I, Nayyar R, Preffer FI. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: Application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom B 2009;76:127-134.
42. Hulspas R, Dombkowski D, Preffer F, Douglas D, Kildew-Shah B, Gilbert J. Flow cytometry and the stability of phycoerythrin-tandem dye conjugates. Cytometry A 2009;75:966-972.
43. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007;21:2046-2049.
44. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, et al. Multi-parameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
45. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-3100. (Pubitemid 35217054)
46. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC. p 202.
47. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-885. (Pubitemid 34639251)
48. Martin P, Santon A, Bellas C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology 2004;44:375-380. (Pubitemid 38491305)
49. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-1299.
50. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, Rapp MJ, Harousseau JL, Amiot M, Bataille R. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:1977-1982. (Pubitemid 28554471)